The AGE Reader measures tissue accumulation of Advanced Glycation Endproducts (AGEs) by means of skin autofluorescence techniques. AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes, cardiovascular disease and renal failure.
Powered by proprietary technology, this revolutionary device is a novel tool for researchers and clinicians for the quantification of AGEs and the risk assessment of cardiovascular diseases, diabetes and renal failure.
The AGE Reader gives a non-invasive cardiovascular risk assessment within one minute.
AGEs accumulate with ageing in normal conditions, but this process occurs more rapidly in patients with conditions such as diabetes and renal failure. The accumulation of AGEs can initiate a wide range of abnormal responses in cells and tissues. Skin AGEs, determined from skin tissue samples, correlate closely with early kidney, eye and nerve disease in patients with diabetes mellitus.
Until now it has been difficult to measure tissue AGEs in patients because existing methods are expensive, time consuming, lack specificity, are poorly reproducible and/or are invasive.
The AGE Reader CU is compact device which features a built-in mini computer and battery and is operated through a touch screen panel.
After the measurement, a direct printout of the report can be made to a connected printer. Optional PC software to perform further analysis on the data is also available.